Testagen

What Is Testagen?

Testagen is a synthetic tetrapeptide with the sequence Lys-Glu-Asp-Gly (KEDG), one of the short peptide bioregulators studied mainly by Russian gerontology research groups. Biochemical papers use the name testagen for this exact sequence, and a 2025 materials study describes it as H-Lys-Glu-Asp-Gly-OH, a peptide with an unmodified amino terminus and a free carboxylic acid terminus.^[1][2]

Published animal studies describe Lys-Glu-Asp-Gly as a peptide designed from the amino acid composition of peptide complexes, sometimes called cytomedins, extracted from the anterior lobe of the pituitary gland.^[3][4] In those experiments it was usually tested side by side with Ala-Glu-Asp-Gly, a tetrapeptide described in the same papers as derived from posterior pituitary extracts and better known elsewhere as epithalon.^[1][4]

The literature on testagen is small. It consists of a series of experiments in hypophysectomized chickens and hens, two in vitro biochemistry papers on how short peptides interact with DNA and histones, and one non-biological study of copper corrosion. No human clinical studies of testagen appear in the PubMed records reviewed for this page.

Chemical Structure and Molecular Identity

Testagen is a linear chain of four standard L-amino acids, lysine, glutamic acid, aspartic acid and glycine, joined by three peptide bonds with free amino and carboxyl termini. The 2025 copper-surface study names the molecule H-Lys-Glu-Asp-Gly-OH and refers to it by the one-letter code KEDG.^[2]

Its side chains give the molecule a mixed charge profile. Lysine carries a basic amino group, while glutamic acid and aspartic acid each carry an acidic carboxyl group, and glycine has no side chain. In the copper study, computational modeling attributed the peptide’s surface binding to a combination of electrostatic, van der Waals and covalent interactions.^[2]

No PubChem compound record was matched to testagen for this page, so a molecular formula, molecular weight and CAS number are not listed here.

Related sequences

Several other short peptide bioregulators share testagen’s Glu-Asp core:

• Epithalon (Ala-Glu-Asp-Gly) differs only at the first residue.
• Vesugen (Lys-Glu-Asp) is testagen’s first three residues.
• Livagen (Lys-Glu-Asp-Ala), prostamax (Lys-Glu-Asp-Pro) and pancragen (Lys-Glu-Asp-Trp) share the same first three residues and differ at position four.

Research History and Development

Published work on Lys-Glu-Asp-Gly began with endocrine studies in birds in 2008 and later expanded to in vitro biochemistry and, in 2025, materials chemistry. The earliest indexed paper reported that the tetrapeptide, synthesized from the amino acid composition of pituitary cytomedins, was tested in neonatally hypophysectomized chickens.^[3]

The same research group followed with studies in chickens and older hens between 2010 and 2013. These examined the thyroid gland, immune and hemostatic parameters and the thymus after surgical removal of the pituitary gland, comparing Lys-Glu-Asp-Gly with Ala-Glu-Asp-Gly.^[5][6][7][4]

In parallel, a biochemistry group that included researchers associated with the bioregulator program published in vitro studies in 2011 and 2013. They used fluorescence methods to test whether testagen and related short peptides enter cells and bind DNA and histone proteins.^[1][8] The most recent paper, from 2025, studied testagen as a possible corrosion inhibitor for copper in salt solution, a use unrelated to biology.^[2]

Mechanisms Studied in Research

Mechanistic research on testagen has focused on whether it can reach the cell nucleus and bind DNA or histones in a sequence-specific way. These studies were performed in cell culture and in cell-free systems, not in living animals.

In HeLa cells, fluorescein-labeled testagen, epithalon and pinealon each produced marked fluorescence in the cytoplasm, nucleus and nucleolus, which the authors interpreted as evidence that short peptides can penetrate into the nucleus. In cell-free tests, testagen, epithalon and pinealon appeared to bind preferentially to deoxyribooligonucleotides containing CAG sequences, and the peptides discriminated between methylated and unmethylated cytosine.^[1]

A follow-up study reported that Lys-Glu-Asp-Gly and five other short peptides bind fluorescein-labeled wheat histones H1, H2B, H3 and H4, apparently through the N-terminal histone regions. The authors proposed that site-specific binding of short peptides to histone tails could act as an epigenetic control mechanism, though this was presented as a hypothesis rather than a demonstrated effect.^[8]

The animal studies did not test a molecular mechanism. They reported downstream changes in thyroid-stimulating hormone, thyroid hormones and tissue structure after the pituitary had been removed.^[5][6]

Key Findings From Published Studies

Most findings on testagen come from hypophysectomized birds, where it was reported to reduce thyroid, thymus, immune and clotting changes caused by pituitary removal. All of the animal work comes from one research group and was published as short reports.

Animal studies in hypophysectomized chickens and hens

• Thyroid function: in neonatally hypophysectomized chickens, administration of Lys-Glu-Asp-Gly or Ala-Glu-Asp-Gly was followed by higher concentrations of thyrotropic hormone and thyroid hormones and recovery of thyroid structure.^[3]
• Effect of age: both tetrapeptides raised TSH, T3 and T4 and limited atrophic thyroid changes, with greater restoration in one-year-old birds than in five-year-old birds.^[5] A related report found the normalizing effect on hormone levels was weaker in old hens than in young chickens.^[6]
• Immunity and hemostasis: neonatal hypophysectomy depressed immunity, increased coagulation and reduced fibrinolysis; the pituitary-derived peptides prevented atrophic thyroid changes and normalized immune and hemostatic parameters.^[7]
• Thymus: both peptides promoted recovery of thymic structure in hypophysectomized birds of different ages, and Lys-Glu-Asp-Gly had a more pronounced effect than Ala-Glu-Asp-Gly.^[4]

In vitro and non-biological studies

Cell and cell-free experiments showed nuclear uptake of labeled testagen in HeLa cells and sequence-dependent binding to DNA fragments and histones.^[1][8] Separately, electrochemical measurements found that KEDG inhibited copper corrosion in sodium chloride solution with an efficiency of around 86 percent, and its adsorption fit a Freundlich isotherm with a standard free energy of adsorption of -30.86 kJ/mol.^[2]

Evidence at a glance

Because these results rest on a few short reports, researchers typically confirm KEDG sequence and purity with HPLC and mass spectrometry certificates of analysis.

Regulatory and Research Status

Testagen is not an FDA-approved drug and has no approved medical use in the United States. It is available only as a research compound, and the published record reviewed here contains no human clinical trials.

The evidence base consists of animal experiments in birds, in vitro biochemistry and one materials science paper.^[3][1][2] The animal findings have not been independently replicated by other groups in the PubMed record, and the mechanistic studies propose, rather than establish, an epigenetic mode of action.

Key gaps include the absence of pharmacokinetic data, toxicology studies, in vivo experiments in mammals and any controlled human research. Most of the biological studies were published as brief reports with short abstracts, which limits the methodological detail available for independent assessment.

Claims about testagen’s effects in humans, including claims about male reproductive health suggested by its name, are not supported by the peer-reviewed abstracts available for this page.